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Abstract
This study investigates the impact of body mass index (BMI) on the prognosis for patients with breast cancer within the 
context of race (African-American versus Caucasian) and ethnicity (Hispanic versus Non-Hispanic). Overall, this study 
included 1,368 female breast cancer patients diagnosed between 2007 and 2010 with electronic medical record data accrued 
from a large Florida hospital network. Non-Hispanic black patients comprised 8.77% of the cohort and Hispanic patients 
made up 7.56%. Multivariate analysis revealed that breast cancer death rate was increased over 2.6-fold for underweight 
patients ubiquitously, regardless of race or ethnicity. Patients overweight or obese did not have an increased hazard rate 
compared to those of normal weight. Importantly, the mechanism for the poorer prognosis for underweight patients needs 
to be defined. We suggest the use of a low BMI as a high-risk factor for breast-cancer mortality in all racial and ethnic 
populations. 
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 Breast cancer is the most common malignancy affect-
ing women, representing 16% of all cancers [1]. In the United 
States, lifetime risk for breast cancer development is approxi-
mately 12% [2]. Although great improvements in disease-free 
survival have been obtained, as many as 2.86% of all women 
in the U.S will die from primary breast cancer (calculated over 
the 2003 – 2005 period). Breast cancer is the second most com-
mon cause of cancer-related death in women [3]. It remains 
critical to identify high-risk patient subgroups to improve pa-
tient outcomes while not subjecting those patients with excel-
lent prognosis to unnecessary therapies.
 The literature notes that African-American women 
have worse health outcomes after a diagnosis of breast cancer 
compared with their Caucasian counterparts [4]. Several stud-
ies have attempted to identify independent risk factors for the 
worse prognosis for African-American women, including later 
stage of diagnosis and treatment options. With the growing 
prevalence of obesity in the U.S. (32.2% of men and 35.5% of 
women), it is impossible to ignore the role of metabolic sta-
tus in breast cancer prognosis, particularly within the context 
of race [5]. However, establishing a single model relationship 
between body mass index (BMI) and breast malignancy re-
mains a point of contention. Historically, it has been suggested 
that high BMI is a risk factor for breast cancer development 
and increased mortality [5-13]. However, more recently, stud-
ies have suggested increased BMI may also be protective from 
mortality [14-18]. The purpose of this study was to determine 
the impact of BMI on outcomes for patients with breast cancer, 
examining a relatively large cohort of diverse Florida women, 
representing the dynamics characteristic of the broader U.S. 
patient population.
Methods
Data collection
 The dataset created for this study is intended to ad-
vance patient-centered outcomes research on complex patients 
within the AHRQ Multiple Chronic Conditions Research Net-
work [19]. This study was designed to compare patient sur-
vival trends using a dataset of hospital patient data linked with 
state cancer registry data. The dataset was created through a 
partnership between the Florida Department of Health, the 
Florida Cancer Data System (FCDS), academic researchers 
from Florida A&M University, the University of Miami and a 
large Florida hospital network. The hospital network provided 
patient electronic medical records (EMRs). EMRs contain 
patient medical and demographic information in greater de-
tail than data elements routinely collected by FCDS, the state 
cancer registry. Invasive breast cancer patients were identi-
fied among patients whose principal diagnosis or a secondary 
diagnosis code was International Classification of Diseases 
(ICD-9-CM) code between 174.0 and 174.9. The EMR records 
of invasive breast cancer patients were then linked to the cen-
tral cancer registry data using unique patient identifiers.
Study subjects in this project were restricted to female breast 
cancer patients with diagnosis and/or treatment data from 
within the partner hospital system between 2007 and 2010. 
Overall, 1,368 female breast cancer patients for whom immu-
nohistochemistry biomarker and BMI data were available were 
identified and included for this study. This study was approved 
by the Florida Department of Health Institutional Review 
Board.
Statistical analysis
 In this study, BMI was measured when patients were 
admitted for treatments. The BMI cut-off points we used to 
define underweight, normal, overweight, class I obese, class II 
obese, and class III obese were 19, 25, 30, 35, 40, with lower 
end included in the interval. The study cohort was divided into 
four (level 1-level 4) socioeconomic groups (SEG) and one 
unknown group based on the proportion of population under 
poverty level in the Census Tract where an individual lived at 
the time of diagnosis. The Elixhauser Index was used to identify 
major coexisting conditions based on the ICD-9 code of inpa-
tient and outpatient administrative data [20]. Age at diagnosis 
was used as a proxy for menopausal status.
 The analysis focused on cause-specific survival from 
breast cancer diagnosis to death due to breast cancer. Patients 
who died due to other reasons or were alive at the end of the 
study were statistically censored, allowing for a complex sur-
vival analysis for death due to breast cancer [21,22]. Descrip-
tive statistics, including sample mean and sample proportion 
were applied to summarize patient characteristics. Population 
means were compared using T tests, while associations between 
categorical variables were assessed using χ2 tests. Within the 
bivariate analyses, survival probability over time was estimated 
for BMI and race/ethnicity categories using the Kaplan-Meier 
estimation method and tested using the log-rank test.
 In order to study the adjusted BMI effect, multivari-
ate survival analysis adjusting for confounders was also carried 
out using the Cox model. Specifically, the multivariate model 
included BMI, age at diagnosis, race/ethnicity, social economic 
status, marital status, health insurance, total comorbidity, triple 
negative marker status, histology information, treatment in-
formation, tumor grade at diagnosis, stage at diagnosis, tumor 
size, number of positive nodes identified, and total number of 
nodes examined. Interactions between BMI and race/ethnicity 
were also included in the multivariate analyses to examine ex-
istence of additional disadvantageous low BMI effect associated 
with Non-Hispanic black and Hispanic populations. To assess 
whether the effect of BMI or any significant covariate differed 
between the pre- and post-menopause subsamples in our data, 
the interaction between age at diagnosis and BMI with other 
significant covariates were tested.
Introduction
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To formally assess whether the adjusted BMI effect was dif-
ferent across stage levels after adjusting for effect of other 
covariates (e.g. whether an increased death rate of being un-
derweight existed for both patients diagnosed with regional or 
distant stage and patients with localized stage), the interaction 
between BMI and stage of diagnosis was tested. Hazard ratios 
were calculated for all variables in the model. The statistical 
analyses were conducted using SAS/STAT® software, Version 
9.3 of the SAS System for Windows (Cary, North Carolina).
Results
Demographic Profile
 The study cohort consisted of 1,368 female breast 
cancer patients diagnosed and treated between 2007 and 2010 
where 106 patients died due to breast cancer during the study. 
Table 1 presents descriptive statistics for the demographic pro-
file of the cohort, tested across non-underweight versus un-
derweight (BMI < 19).
Table 1: Patient characteristics and relation with underweight (N = 1,368)
Variable Percentage Non-underweight* Underweight* P-Value
BMI Under weight 4.02 
Normal 33.04 
Overweight 29.68 
Obese I 18.20 
Obese II 8.99 
Obese III 6.07 
Age at dx Age at dx <= 50 25.66 25.29 34.55 0.1546
Age at dx > 50 74.34 74.71 65.45
Race/Ethnicity NH white 83.67 83.62 84.91 0.6570
NH black 8.77 8.90 5.66
Hispanic 7.56 7.48 9.43
Social economic 
status**
SEG 1 13.60 13.33 20.00 0.2308
SEG 2 33.48 33.59 30.91
SEG 3 30.34 30.77 20.00
SEG 4 20.83 20.64 25.45
Unknown 1.75 1.68 3.64
Married Single 45.32 45.16 49.09 0.8385
Married 51.17 51.33 47.27
Unknown 3.51 3.50 3.64
Insurance Not insured 3.00 2.89 5.45 0.6711
Medicaid 8.11 8.00 10.91
Medicare 32.68 32.75 30.91
Private insurance 53.80 54.00 49.09
Unknown 2.41 2.36 3.64
Total comorbidity 0.65 (1.29) 0.65 (1.31) 0.49 (0.96) 0.2330
* column % or mean (std. dev.)
** SEG 1 = “> 20% living in poverty”, SEG 2 = “Between 10% and <20% of population living in poverty”, SEG 3 = “Between 5% and 
<10% of population living in poverty”, SEG 4 = “< 5% of population living in poverty”
Most patients were diagnosed at ages 50 years and older 
(74.34%). Non-Hispanic white patients comprised 83.67% and 
Non-Hispanic black patients comprised 8.77% of the cohort. 
Hispanic patients made up 7.56%. Importantly, the distribu-
tion of race/ethnicity status was not statistically different be-
tween non-underweight and underweight. 
 Most patients were married (51.17 %) and had pri-
vate health insurance (53.80%). A large proportion (32.68%) 
of patients were Medicare beneficiaries. Finally, on average, 
each patient had 0.65 comorbidities (or approximately 2 co-
morbidities per 3 patients) at diagnosis. No statistically signifi-
cant difference between underweight and non-underweight 
was noted in SEG, marital status, insurance status, or number 
of comorbidities.
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Clinical Profile
 Table 2 provides descriptive clinical profile for the co-
hort. The data also assessed the three most commonly tested 
biochemical markers in breast cancer: Estrogen Receptor (ER), 
Progesterone receptor (PR), and Human Epidermal Growth 
Factor Receptor 2 (HER-2). 
Table 2: Tumor characteristics and treatment, and relation with underweight (N = 1,368)
Variable Percentage Non-underweight* Underweight* P-Value
ER - 18.64 18.20 29.09 0.1151
+ 76.54 77.00 65.45
Unknown 4.82 4.80 5.45
PR - 32.75 32.29 43.64 0.2006
+ 61.99 62.45 50.91
Unknown 5.26 5.26 5.45
HER2 - 42.91 42.80 45.45 0.6140
+ 11.40 11.58 7.27
Unknown 45.69 45.62 47.27
Triple Negative No 79.61 79.97 70.91 0.1168
Yes 6.29 6.32 5.45
Unknown 14.11 13.71 23.64
Breast surgery No surgery 2.19 2.13 3.64 0.0772
Mastectomy 40.13 39.98 43.64
Other surgery 49.20 49.73 36.36
Unknown 8.48 8.15 16.36
Hormone No 74.34 74.26 76.36 0.5362
Yes 23.54 23.53 23.64
Unknown 2.12 2.21 0.00
Radiation No 66.59 66.49 69.09 0.2464
Yes 32.97 33.13 29.09
Unknown 0.44 0.38 1.82
Chemo No 54.02 53.92 56.36 0.8750
Yes 41.30 41.43 38.18
Unknown 4.68 4.65 5.45
Stage Localized 56.51 56.97 45.45 0.0007
Regional 33.77 33.89 30.91
Distant 5.77 5.26 18.18
Unknown/un-
staged 
3.95 3.88 5.45
Grade Well-differentiated 19.08 19.27 14.55 0.1262
Moderately-differ-
entiated
37.87 38.23 29.09
Poorly- or un-
differentiated
43.06 42.50 56.36
Histology Ductal 83.77 83.93 80.00 0.4992
Lobular 10.67 10.66 10.91
Other 5.56 5.41 9.09
Tumor Size (mm) 24.40 (22.62) 24.24 (22.45) 28.05 (26.35) 0.2210
Number of positive 
nodes examined
1.29 (2.98) 1.27 (2.95) 1.95 (3.63) 0.1775
Total number of 
nodes examined
6.88 (7.90) 6.97 (7.94) 4.65 (6.48) 0.0329
* column % or mean (std. dev.)
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None of the distributions of the three markers differed signifi-
cantly between underweight and non-underweight. “Triple 
negative” status (or the lack of all three markers) did not differ 
between the two groups significantly.
 The distribution of stage of cancer at diagnosis was 
statistically different between the two groups (Underweight vs. 
Non-Underweight, P = 0.0007) in the bivariate relationship. 
Underweight patients were more likely to have distant (18.18% 
vs. 5.26%) or unknown stage of disease (5.45% vs. 3.88%) com-
pared with their non-underweight counterparts. However, the 
pathologic grade did not differ significantly. 
Breast Cancer Outcomes
 The two-year survival of the cohort was estimated to 
be 94.7%. The median follow-up time for those who died di-
rectly due to breast cancer was 709 days. Figure 1 (a) shows a 
Kaplan-Meier survival estimate by BMI category. The under-
weight category carried the poorest survival prognosis; and 
the survival for overweight or obese patients in our cohort 
was not significantly different from those of normal weight. 
As shown in Figures 1 (b) and 1 (c), when stratified by diag-
nosis stage, the lowest survival prognosis was still observed for 
underweight patients in localized as well as in regional and 
distant stages.
 (a) Kaplan-Meier survival estimates for combined data (N = 1368)
(b) Kaplan-Meier survival estimates for localized stage (N = 773)
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(c) Kaplan-Meier survival estimates for regional and distant stages (N = 541)
 
Figure 1 Kaplan-Meier survival estimates by BMI category.
This observation was consistent with test result based on the 
multivariate model after covariate adjustment.
 Figure 2 compares Kaplan Meier survival estimates 
for Non-Hispanic white, Non-Hispanic black, and Hispanic 
patients. The race/ethnicity comparison in the figure indicates 
survival probability
for Non-Hispanic black was the lowest for most of the study 
time. Although the bivariate racial comparison between Cau-
casian and African-American patients showed significant dif-
ference (P = 0.0465), the comparison among Non-Hispanic 
white, Non-Hispanic, black, and Hispanic patients was not 
significant (P = 0.2522). 
 Table 3 presents a multivariate survival analysis of a 
multitude of variables that may influence time from diagnosis 
to death due to breast cancer.
Figure 2: Kaplan-Meier Survival Estimate by Race/Ethnicity (N = 1323)
Table 3 multivariate survival analysis of time to breast cancer death (N = 1,292)
Variable Hazard Ratio 95% CI P-Value
BMI (vs. Normal 
weight)
Underweight  2.612 1.200 5.685 0.0156 
Overweight  1.130 0.638 2.004 0.6752 
Obese  1.710 0.965 3.030 0.0660 
Age at dx (vs. <= 
50)
Age at dx > 50  0.713 0.418 1.217 0.2152 
Race/Ethnicity (vs. 
NH white)
NH black  1.272 0.598 2.704 0.5317 
Hispanic  0.678 0.260 1.767 0.4260 
Social economic 
status (vs. SEG 4)*
SEG 1  0.574 0.258 1.280 0.1753 
SEG 2  0.592 0.310 1.131 0.1124 
SEG 3  0.902 0.497 1.637 0.7346 
Unknown  0.370 0.062 2.221 0.2770 
Married (vs. Mar-
ried)
Single  1.071 0.670 1.711 0.7749 
Unknown  0.628 0.139 2.843 0.5462 
Insurance (vs. Pri-
vate insurance)
Not insured  2.246 0.814 6.198 0.1181 
Medicaid  1.766 0.930 3.354 0.0821 
Medicare  2.422 1.394 4.208 0.0017 
Total comorbidity  0.914 0.791 1.056 0.2206 
Triple Negative (vs. 
Non-Triple Nega-
tive)
Triple Negative  8.514 3.940 18.400 <.0001 
Unknown  4.501 2.663 7.607 <.0001 
Breast surgery (vs. 
No surgery)
Mastectomy  2.848 0.899 9.016 0.0751 
Other surgery  3.398 0.997 11.582 0.0505 
Unknown  4.768 1.588 14.316 0.0054 
Hormone (vs. No-
Hormone)
Hormone  1.205 0.603 2.410 0.5976 
Unknown  1.572 0.135 18.335 0.7181 
Radiation (vs. No-
Radiation)
Radiation  1.407 0.830 2.384 0.2043 
Unknown  2.895 0.461 18.175 0.2567 
Chemo (vs. No-
Chemo)
Chemo  1.117 0.699 1.784 0.6446 
Unknown  0.999 0.233 4.283 0.9994 
Stage (vs. Local-
ized)
Regional  1.883 0.931 3.809 0.0783 
Distant 10.522 4.950 22.367 <.0001 
Unknown/un-
staged 
 4.455 1.923 10.322 0.0005 
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Grade (vs. Well-
differentiated)
Moderately-differ-
entiated
 3.318 0.761 14.470 0.1104 
Poorly- or un-
differentiated
 4.109 0.955 17.682 0.0577 
Histology (vs. 
Ductal)
Lobular  1.299 0.659 2.561 0.4496 
Other  0.621 0.290 1.329 0.2201 
Tumor Size (mm)  1.015 1.008 1.022 <.0001 
Number of positive 
nodes examined
 1.160 1.087 1.238 <.0001 
Total number of 
nodes examined
 0.957 0.919 0.995 0.0281 
Underweight x NH 
black
 0.425 0.3993 
Underweight x 
Hispanic
 0.560 0.6320 
* SEG 1 = “> 20% living in poverty”, SEG 2 = “Between 10% and <20% of population living in poverty”, SEG 3 = “Between 5% and 
<10% of population living in poverty”, SEG 4 = “< 5% of population living in poverty”
The breast cancer death rate for underweight patients was 
found to be 2.61 times that of normal weight patients (P = 
0.0156). The BMI-race/ethnicity interactions were not statisti-
cally significant, indicating the disadvantageous effect for un-
derweight patients was not different among the Non-Hispanic 
white, Non-Hispanic black, or Hispanic patients. However, pa-
tients who were Medicare beneficiaries had a 2.42-fold higher 
rate of death compared to those with health insurance other 
than Medicare or Medicaid (P = 0.0017). No interaction be-
tween age at diagnosis or any other significant covariate (in-
cluding BMI) met the 0.05 significance level for entry into the 
multivariate model, suggesting no significant difference be-
tween pre- and post-menopausal patients.
 The p-value for the interaction between BMI and 
stage of disease did not meet the 0.05 significance level for en-
try into the model either, suggesting that the adjusted elevated 
risk for breast cancer death among underweight patients ap-
plied to all tested stages (local, regional, and distant).
 The multivariate analysis (Table 3) found several 
other factors associated with higher breast cancer death rate 
including triple negative or unknown biomarker status, larg-
er tumor size, having more positive nodes, having unknown 
surgery information, and having distant or unknown stage at 
diagnosis. Interestingly, having more nodes examined was as-
sociated with reduced breast cancer death rate. Notably, being 
overweight or obese was not found to be significantly associ-
ated with increased risk of breast cancer death in our model.
Discussion
 This study suggests that being underweight (BMI < 
19) is a poor predictive factor for female breast cancer patients. 
The risk of death in the underweight breast cancer patient 
group was significantly higher – with over a 2.6 fold increased 
risk of mortality (Table 3). The survival probabilities for the 
underweight group drop precipitously at approximately two-
years following diagnosis (Figure 1 (a)). Interestingly, despite 
patients with distant disease being more likely to be under-
weight than not (18.18% vs. 5.26%), underweight patients 
also tended to have fewer nodes sampled on average (4.65 
vs. 6.97, P = 0.0329) without a significant increase in rate of 
node-positivity (P = 0.1775). As stated earlier, our data noted 
that the hazard ratio for underweight patients (compared with 
normal) did not vary across stage (not illustrated). This sug-
gests that stage-related course of disease plays less of a role in 
the worsened prognosis of having a low BMI. Qualitative com-
parisons of trends in Figures 1 (b) and 1 (c) show that both low 
stage and high stage breast cancers have stronger association 
with higher mortality in underweight patients.
 This study found that the effect of being underweight 
on increased mortality was equally distributed among the 
three race/ethnicity groups in our model. The breast cancer 
literature notes that African-Americans have worse outcomes 
in many measures including mortality [4]. In fact, it is noted 
that harmful predictive factors tend to disproportionately af-
fect African-Americans. Our data is significant in the identifi-
cation of a clinical and demographic risk factor that is ubiqui-
tous among the cohort. The finding of this study suggests that 
underweight patients may be identified as a high-risk group 
assessed in all racial and ethnic populations.
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 Moon et al., 2009 examined 24,698 Korean breast 
cancer patients and also found underweight status was an 
independent harmful prognostic factor for overall survival 
and breast cancer-specific survival [16]. Similarly, Caan et al., 
2012 examined weight change and identified that a significant 
weight loss correlated with overall worse prognosis, particu-
larly for those who were leaner at baseline [23]. Taken togeth-
er, these data support the idea of an “obesity paradox” whereby 
being normal or even overweight is protective following the 
diagnosis of breast cancer but that being leaner is harmful. 
This phenomenon is more commonly described in chronic 
heart failure and other chronic wasting conditions [24-26].
 A few limitations exist in our study. The data are ret-
rospective in nature and although disease-specific data also 
were available, their accuracy could not be independently 
confirmed. Furthermore, in using only BMI as an indicator 
for weight status, the analyses ignore and possibly confound 
relationships with body composition, adiposity, and adipose 
distribution. However, BMI is accepted by the World Health 
Organization as an acceptable measure of stratification and 
classification [27]. While age at diagnosis was determined, 
menopause status in the patients was not. We opted for a 
strictly quantitative measure of menopausal status (with the 
age of 50 as the cutoff) because of variability in its clinical re-
porting. Finally, while our multivariate analysis and validation 
of underweight hazard by stage stratification attempt to reduce 
confounding, it is important to note the chance that patients 
in low BMI strata are leaner as a function of their poor health 
status, which in turn might reduce survival rates.
 A major strength of our study is in our statistical 
analysis of all four BMI groups—underweight, normal, over-
weight, and obese—within the context of a single comparative 
multivariate analysis and K-M survival analysis plot. Many 
studies, such as Ewertz et al., 2010, Chen et al., 2012, and 
Huang et al., 1997, only assessed up to two of these groups 
[11,14,18]. Moon et al., 2009 notes how a common limitation 
in several studies of this field is in putting underweight pa-
tients in the same group as normal patients such as in Dawood 
et al., 2008 [16,28]. Although Moon et al., 2009 does study all 
of these groups individually, they also state that their patient 
sample is limited to a homogenous and ethnically similar pool 
that may not be generalizable to other ethnic groups [16]. As 
stated earlier, survival rates for breast cancer among the races 
in the United States may differ significantly [29]. By maintain-
ing the heterogeneity of our serving population, this study has 
been able to identify underweight BMI as a cross-racial and 
cross-ethnic risk factor.
Conclusion
 Breast cancer is a heterogeneous disease where biol-
ogy meets demographics. This study suggests that a low BMI 
at diagnosis is a poor prognostic factor despite any strong de-
mographic interplay. Specifically, the ubiquity of the effect of 
BMI on mortality suggests an underlying biologic process that 
crosses racial and ethnic boundaries. The identification of pos-
sible novel variable genetic, proteomic, and hormonal expres-
sion profiles in patients with breast cancer at various levels of 
BMI might further clarify the apparent paradox reported in the 
relationship of metabolic status to malignancy related mortal-
ity. Moving forward, the clinical translation and applicability 
of BMI to breast cancer may have substantial implications on 
breast cancer prognosis and treatment, especially considering 
the current climate of broad avocation for the multi-omic and 
metabolic consequences of malignancy.
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